Apokyn, Ixense(apomorphine)
Apokyn, Apomorphine, Ixense, Onapgo, Taluvian, Uprima (apomorphine) is a small molecule pharmaceutical. Apomorphine was first approved as Uprima on 2001-05-28. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat erectile dysfunction. The pharmaceutical is active against D(3) dopamine receptor, D(4) dopamine receptor, and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2B, alpha-2B adrenergic receptor, transient receptor potential cation channel subfamily A member 1, D(1A) dopamine receptor, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Apokyn, Apomorphine, Onapgo (discontinued: Apokyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Apomorphine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| APOKYN | MDD US Operations | N-021264 RX | 2004-04-20 | 1 products, RLD, RS |
| ONAPGO | MDD US Operations | N-214056 RX | 2025-02-03 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| apokyn | New Drug Application | 2024-10-10 |
| apomorphine hydrocloride | ANDA | 2022-02-24 |
| onapgo | New Drug Application | 2025-08-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
APOMORPHINE HYDROCHLORIDE, KYNMOBI, SUNOVION PHARMS INC | |||
| 2023-05-21 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Apomorphine Hydrochloride, Kynmobi, Sunovion Pharms Inc | |||
| 10449146 | 2036-04-19 | U-2825 | |
| 10959943 | 2036-04-19 | U-2825 | |
| 8414922 | 2031-12-16 | DP | U-2825 |
| 8846074 | 2031-12-16 | DP | U-2825 |
| 11419769 | 2031-12-16 | DP | U-2825 |
| 9044475 | 2030-06-11 | DP | |
| 9283219 | 2030-06-11 | DP | U-2825 |
| 9326981 | 2030-06-11 | U-2825 | |
| 9669019 | 2030-06-11 | DP | U-2825 |
| 9669021 | 2030-06-11 | U-2825 | |
| 10420763 | 2030-06-11 | DP | U-2825 |
| 10821074 | 2029-08-07 | DP | |
| 8603514 | 2024-04-03 | DP | |
| 8765167 | 2024-02-20 | DP | |
| 8663687 | 2023-02-02 | DP | |
HCPCS
Code | Description |
|---|---|
| J0364 | Injection, apomorphine hydrochloride, 1 mg |
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 15 | 18 | 6 | 12 | 50 |
| Motor disorders | D000068079 | — | — | — | — | — | 2 | — | 2 |
| Low back pain | D017116 | — | M54.5 | — | — | — | 1 | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | 1 | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | 1 | — | 1 |
| Vomiting | D014839 | — | R11.1 | — | — | — | 1 | — | 1 |
| Nausea | D009325 | — | R11.0 | — | — | — | 1 | — | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | 1 | — | 1 |
| Psychomotor agitation | D011595 | — | — | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Consciousness disorders | D003244 | — | — | — | 2 | 1 | — | — | 2 |
| Persistent vegetative state | D018458 | — | R40.3 | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | — | G24 | — | 1 | — | — | — | 1 |
| Hallucinations | D006212 | — | F06.0 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | — | — | — | 1 |
| Brain injuries | D001930 | — | S06.9 | — | 1 | — | — | — | 1 |
| Parkinsonian disorders | D020734 | — | G20.C | — | 1 | — | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleepiness | D000077260 | — | R40.0 | — | — | — | — | 1 | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | G31.85 | — | — | — | — | 1 | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 1 | 1 |
| Generalized epilepsy | D004829 | — | — | — | — | — | — | 1 | 1 |
| Hyperkinesis | D006948 | — | — | — | — | — | — | 1 | 1 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | — | — | — | 1 | 1 |
| Cancer pain | D000072716 | — | G89.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Apomorphine |
| INN | — |
| Description | Apomorphine is an aporphine alkaloid. It has a role as an alpha-adrenergic drug, a serotonergic drug, an antidyskinesia agent, a dopamine agonist, an antiparkinson drug and an emetic. It derives from a hydride of an aporphine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3 |
Target
Alternate
HTR2B
HTR2B
ADRA2B
ADRA2B
TRPA1
TRPA1
DRD1
DRD1
DRD5
DRD5
HTR2A
HTR2A
HTR1A
HTR1A
HTR2C
HTR2C
ADRA2A
ADRA2A
ADRA2C
ADRA2C
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Apokyn – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,475 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,024 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use